MCID: PNM007
MIFTS: 68

Pneumonia

Categories: Infectious diseases, Respiratory diseases

Summaries for Pneumonia

MedlinePlus : 42 Pneumonia is an infection in one or both of the lungs. Many germs, such as bacteria, viruses, and fungi, can cause pneumonia. You can also get pneumonia by inhaling a liquid or chemical. People most at risk are older than 65 or younger than 2 years of age, or already have health problems. Symptoms of pneumonia vary from mild to severe. See your doctor promptly if you Have a high fever Have shaking chills Have a cough with phlegm that doesn't improve or gets worse Develop shortness of breath with normal daily activities Have chest pain when you breathe or cough Feel suddenly worse after a cold or the flu Your doctor will use your medical history, a physical exam, and lab tests to diagnose pneumonia. Treatment depends on what kind you have. If bacteria are the cause, antibiotics should help. If you have viral pneumonia, your doctor may prescribe an antiviral medicine to treat it. Preventing pneumonia is always better than treating it. Vaccines are available to prevent pneumococcal pneumonia and the flu. Other preventive measures include washing your hands frequently and not smoking. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pneumonia, also known as acute pneumonia, is related to mycoplasma pneumoniae pneumonia and cryptogenic organizing pneumonia, and has symptoms including fever, pruritus and hemoptysis. An important gene associated with Pneumonia is TTR (Transthyretin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Minocycline and Methylnaltrexone have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing.

CDC : 3 Pneumonia is an infection of the lungs that can cause mild to severe illness in people of all ages. Depending on the cause, doctors often treat pneumonia with medicine. In addition, vaccines can prevent some types of pneumonia. However, it is still the leading infectious cause of death in children younger than 5 years old worldwide. Common signs of pneumonia include cough, fever, and difficulty breathing. You can help prevent pneumonia and other respiratory infections by following good hygiene practices. These practices include washing your hands regularly and disinfecting frequently touched surfaces. Making healthy choices, like quitting smoking and managing ongoing medical conditions, can also help prevent pneumonia.

PubMed Health : 62 About pneumonia: Pneumonia (nu-MO-ne-ah) is an infection in one or both of the lungs. Many germs—such as bacteria, viruses, and fungi—can cause pneumonia. The infection inflames your lungs' air sacs, which are called alveoli (al-VEE-uhl-eye). The air sacs may fill up with fluid or pus, causing symptoms such as a cough with phlegm (a slimy substance), fever, chills, and trouble breathing.

Wikipedia : 74 Pneumonia is an inflammatory condition of the lung affecting primarily the small air sacs known as... more...

Related Diseases for Pneumonia

Diseases in the Pneumonia family:

Viral Pneumonia Bacterial Pneumonia

Diseases related to Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2211)
# Related Disease Score Top Affiliating Genes
1 mycoplasma pneumoniae pneumonia 35.7 TNF SFTPD IL6 IL10 CRP CD40LG
2 cryptogenic organizing pneumonia 35.5 TNF SFTPD CXCL8 CRP CD40LG
3 viral pneumonia 35.4 TNF SFTPD IL6 IL10 CXCL8 CRP
4 chlamydia pneumonia 35.4 TNF TLR4 IL6 IL1B IL10 CXCL8
5 bacterial pneumonia 35.4 TNF TLR4 SFTPD IL6 IL1B IL10
6 eosinophilic pneumonia 35.4 SFTPD IL6 CXCL8
7 idiopathic interstitial pneumonia 35.3 SFTPD MUC5B ELANE CXCL8 CCL2
8 streptococcus pneumonia 35.3 TNF TLR4 IL6 IL1B IL10 CXCL8
9 aspiration pneumonia 35.3 IL6 CRP CD40LG
10 chronic eosinophilic pneumonia 35.2 IL6 CSF3 CCL3 CCL2
11 nonspecific interstitial pneumonia 35.2 SFTPD MUC5B CCL2
12 lymphoid interstitial pneumonia 35.2 TNF IL6 FOXP3 CRP CD40LG
13 anaerobic pneumonia 35.0 TNF MPO IL6 IL1B
14 pneumocystosis 34.8 TNF SFTPD IL6 CSF3 CRP CD40LG
15 bronchopneumonia 34.6 TNF TLR4 MPO IL6 IL1B IL10
16 pulmonary fibrosis, idiopathic 34.6 TNF TLR4 SFTPD MUC5B IL6 IL1B
17 legionnaire disease 34.5 TLR4 CRP CD40LG
18 influenza 34.1 TNF TLR4 IL6 IL1B CXCL8 CCL2
19 aspiration pneumonitis 34.1 TNF CXCL8 CRP
20 q fever 33.8 TNF TLR4 IL6 IL1B IL10 CD40LG
21 bronchiolitis obliterans 33.7 TNF TLR4 SFTPD MPO IL6 IL10
22 avian influenza 33.7 TNF SFTPD IL6 CXCL8
23 melioidosis 33.6 TNF TLR4 IL6 IL10 CSF3
24 bronchiolitis 33.6 TNF TLR4 SFTPD IL6 IL10 CXCL8
25 respiratory failure 33.6 TTR TNF TLR4 SFTPD MPO IL6
26 toxic shock syndrome 33.6 TNF TLR4 IL6 IL1B IL10 CXCL8
27 chickenpox 33.5 TNF IL6 IL10 CRP CD40LG
28 erythema multiforme 33.5 TNF IL6 CXCL8
29 legionellosis 33.5 TNF TLR4 IL6 IL1B CXCL8 CXCL2
30 lung disease 33.5 TNF TLR4 SFTPD MUC5B MPO IL6
31 interstitial lung disease 33.5 TNF SFTPD MUC5B IL6 IL1B IL10
32 measles 33.4 TNF TLR4 IL6 IL1B CXCL8 CD40LG
33 bacterial meningitis 33.4 TNF TLR4 IL6 IL1B IL10 CXCL8
34 chronic granulomatous disease 33.4 TNF MPO IL1B ELANE CXCL8 CSF3
35 extrinsic allergic alveolitis 33.4 SFTPD MPO IL6 IL1B IL10 ELANE
36 pulmonary disease, chronic obstructive 33.3 TNF TLR4 SFTPD MUC5B MPO IL6
37 adult respiratory distress syndrome 33.3 TNF SFTPD MPO IL6 IL1B IL10
38 invasive aspergillosis 33.3 TLR4 SFTPD IL10 CXCL8 CSF3
39 tularemia 33.3 TNF TLR4 IL1B CD40LG
40 common cold 33.3 TNF TLR4 IL6 IL1B IL10 CXCL8
41 herpes zoster 33.3 TNF IL10 CRP CD40LG
42 plague 33.3 TNF TLR4 IL6 IL1B IL10
43 stroke, ischemic 33.3 TNF TLR4 IL6 IL1B CRP CCL3
44 pyuria 33.3 IL6 CXCL8 CRP CD40LG
45 silicosis 33.2 TNF TLR4 SFTPD IL1B IL10 CXCL8
46 ascaris lumbricoides infection 33.2 IL6 IL1B IL10 CXCL8
47 severe cutaneous adverse reaction 33.2 TNF CRP CD40LG
48 good syndrome 33.2 TNF CRP CD40LG
49 pasteurellosis 33.2 MPO ELANE CXCL8
50 common variable immunodeficiency 33.2 TNF MPO IL6 IL1B IL10 FOXP3

Graphical network of the top 20 diseases related to Pneumonia:



Diseases related to Pneumonia

Symptoms & Phenotypes for Pneumonia

UMLS symptoms related to Pneumonia:


fever, pruritus, hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Pneumonia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 CD40LG CRP CXCL2 FOXP3 IL10 IL1B
2 hematopoietic system MP:0005397 10.03 CD40LG CSF3 ELANE FOXP3 IL10 IL1B
3 homeostasis/metabolism MP:0005376 9.97 CD40LG CRP ELANE FOXP3 IL10 IL1B
4 immune system MP:0005387 9.8 CCL2 CD40LG CRP CSF3 ELANE FOXP3
5 integument MP:0010771 9.28 CD40LG CSF3 ELANE FOXP3 IL10 IL1B

Drugs & Therapeutics for Pneumonia

PubMed Health treatment related to Pneumonia: 62

Treatment for pneumonia depends on the type of pneumonia you have and how severe it is. Most people who have community-acquired pneumonia—the most common type of pneumonia—are treated at home. The goals of treatment are to cure the infection and prevent complications.

Drugs for Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 880)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
2
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
3
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
4
Magnesium oxide Approved Phase 4 1309-48-4 14792
5
Magnesium citrate Approved Phase 4 3344-18-1
6 Cranberry Approved, Investigational Phase 4
7
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
8
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
9
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
10
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
11
Polyestradiol phosphate Approved Phase 4 28014-46-2
12
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
13
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
14
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
15
Budesonide Approved Phase 4 51333-22-3 63006 5281004
16
Dibekacin Approved Phase 4 34493-98-6
17
Lumefantrine Approved Phase 4 82186-77-4 6437380
18
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
19
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
20
Oxacillin Approved, Investigational Phase 4 66-79-5 6196
21
Sucralfate Approved Phase 4 54182-58-0
22
Netilmicin Approved, Investigational Phase 4 56391-56-1 6857423 441306
23
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
24
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
25
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
26
Cefoxitin Approved Phase 4 35607-66-0 441199
27
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
28
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
29
Haloperidol Approved Phase 4 52-86-8 3559
30
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
31
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
32
Desflurane Approved Phase 4 57041-67-5 42113
33
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
34
Probenecid Approved, Investigational Phase 4 57-66-9 4911
35
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
36
Tazobactam Approved Phase 4 89786-04-9 123630
37
Piperacillin Approved Phase 4 66258-76-2 43672
38
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
39
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
40
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
41
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
42
Bromhexine Approved Phase 4 3572-43-8
43
Sulfisoxazole Approved, Vet_approved Phase 4 127-69-5 5344
44
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
45
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
46
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
47
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
48
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
49
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
50
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253

Interventional clinical trials:

(show top 50) (show all 3550)
# Name Status NCT ID Phase Drugs
1 Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia: A Pilot Study Unknown status NCT02478710 Phase 4 Aerosolized Tobramycin or Vancomycin;Aerosolized Placebo
2 Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification Unknown status NCT01546974 Phase 4
3 Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial. Unknown status NCT01492387 Phase 4
4 Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia: A Multicenter Randomized Controlled Clinical Trial Unknown status NCT02913118 Phase 4 Andrographolid Sulfonate Injection (AS Injection);Cephalosporin;Azithromycin, Minocycline or Doxycycline;Amoxicillin-clavulantic acid;Fluoroquinolones;Placebo
5 Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit. Unknown status NCT01883596 Phase 4 0.12% chlorhexidine solution;Placebo
6 Efficacy of Methylprednisolone in Severe Community-acquired Pneumonia,A Multi-center Randomized Controlled Trial Unknown status NCT02552342 Phase 4 methylprednisolone;Normal saline
7 Randomized Controlled Trial of Fermented Dairy Product Containing L. Casei Shirota for Prevention of Ventilator-Associated Pneumonia Unknown status NCT01301131 Phase 4
8 Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment Unknown status NCT02440828 Phase 4 tobramycin inhalation;placebo
9 Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Vitro and in Ventilator-associated Pneumonia Unknown status NCT01356472 Phase 4 Imipenem/cilastatin
10 Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Community-acquired Pneumonia (CAP) in Adults Unknown status NCT03400735 Phase 4 Cefdinir 300Mg Capsule
11 Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months Unknown status NCT01028326 Phase 4
12 SELECTIVE DIGESTIVE DECONTAMINATION USING ORAL GENTAMICIN AND ORAL POLYMYXIN E FOR ERADICATION OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE CARRIAGE IN HOSPITALIZED PATIENTS Unknown status NCT01761487 Phase 4
13 Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Pneumonia: Multi-centre, Prospective, Randomized Controlled Study Unknown status NCT00936013 Phase 4 oseltamivir;oseltamivir and chinese medicinal herbs
14 Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia Unknown status NCT01805284 Phase 4 Linezolid
15 Use Of High Dose Colistin in Multi Drug Resistant Gram Negative Infections in Critically Ill Adult Patients. Randomized Controlled Clinical Trial Unknown status NCT02162966 Phase 4 High Dose Colistin;Standard Dose Colistin
16 Comparison of the Incidence of Ventilator Associated Pneumonia in Patients Intubated With the Taper Guard Endotracheal Tube Versus a Normal Endotracheal Tube Unknown status NCT01501227 Phase 4
17 Evaluation of a Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients Unknown status NCT02600806 Phase 4 Azithromycin;Levofloxacin
18 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics? Unknown status NCT02171338 Phase 4
19 Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration Factors Unknown status NCT00752947 Phase 4 moxifloxacin;levofloxacin;metronidazole
20 The Impact of Lactobacillus Preparation on the Incidence of Diarrhea in Intensive Care Unit-admitted Patients : Randomized Controlled Trial Unknown status NCT01792739 Phase 4 Lactobacillus casei variety rhamnosus granules;Placebo
21 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
22 Effect of Vitamin D Supplementation in Young Children With Acute Lower Respiratory Tract Infection at Dr George Mukhari Academic Hospital, Pretoria, South Africa Unknown status NCT02054182 Phase 4 Vitamin D
23 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
24 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
25 A Multicentre, Randomized, Clinical Trial of Noninvasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure - NINAVAPed Protocol Unknown status NCT01873521 Phase 4
26 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
27 Effects of Dexmedetomidine on Swallowing Function: a Randomized, Double-Blind Study in Healthy Volunteers Unknown status NCT03390972 Phase 4 Placebo;Dexmedetomidine
28 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
29 Residual Neuromuscular Blockade in Cardiac Surgery Patients Unknown status NCT03574337 Phase 4 Sugammadex;neostigmine/glycopyrolate
30 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
31 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
32 The Effect of Selenium Supplementation Among Pediatric Patients With Burns Unknown status NCT00860379 Phase 4 Selenium1;Selenium2;Placebo
33 Oxepa in Multiple Trauma: Prospective, Randomized, Comparative, Double-blind, Controlled Clinical Study Unknown status NCT01099501 Phase 4
34 Prospective, Interventional Multicentre Study on the Effect of Deepening of Sedation on Intra-abdominal Pressure Unknown status NCT02944292 Phase 4 Propofol
35 Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume: a Randomized, Double-Blind Study in Healthy Volunteers Unknown status NCT03283020 Phase 4 RemifentanilMNTX;PlaceboMNTX
36 Phase IV, Prospective, Randomized Study Comparing Preparation the Day Before and Split-dose Regimen With Sodium Picosulphate/Magnesium Citrate for Morning Colonoscopies Unknown status NCT01481714 Phase 4 Sodium picosulphate, magnesium oxid and citric acid;Sodium picosulphate/magnesium oxide and citric acid
37 A Double-blind,Randomized,Parallel,Placebo-controlled Study of Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
38 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
39 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
40 Reinforced Sternal Closure Using Osteoconductive Biologic Bone Cement (Kryptonite) in Patients Undergoing Coronary Artery Bypass Grafting Unknown status NCT01261858 Phase 4
41 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
42 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
43 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
44 Efficacy of Toothbrushing for the Prevention of Ventilator-associated Pneumonia Completed NCT01477099 Phase 4
45 Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas Completed NCT00538018 Phase 4 Telithromycin
46 Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP) Completed NCT01524302 Phase 4 Ceftaroline;Levofloxacin
47 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
48 Comparison of Immune Response in Pneumococcal Pneumonia and After Vaccination Completed NCT01402245 Phase 4
49 Clinical Efficacy of Amoxicillin Given Twice or Three Times a Day Among Children With Non-severe Community-acquired Pneumonia Completed NCT01200706 Phase 4 Amoxicillin
50 Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months

Search NIH Clinical Center for Pneumonia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acetylcysteine
Oxygen
Sucralfate

Cochrane evidence based reviews: pneumonia

Genetic Tests for Pneumonia

Genetic tests related to Pneumonia:

# Genetic test Affiliating Genes
1 Pneumonia 29

Anatomical Context for Pneumonia

MalaCards organs/tissues related to Pneumonia:

40
Lung, Testes, Heart, Colon, Neutrophil, Brain, Kidney

Publications for Pneumonia

Articles related to Pneumonia:

(show top 50) (show all 31855)
# Title Authors PMID Year
1
Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment. 42
32529517 2020
2
Uric Acid Elevation by Favipiravir, an Antiviral Drug. 42
32536670 2020
3
Epidemiological Measures in the Context of the COVID-19 Pandemic. 42
32527379 2020
4
Secretory immunoglobulin A abrogates inflammatory responses and improves mortality after pseudomonas pneumonia. 61 54
20386278 2010
5
[Serum levels of IL-13 and TNF-alpha in children with Mycoplasma pneumoniae pneumonia]. 61 54
20416219 2010
6
Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumonia. 61 54
19825784 2010
7
The impact of time on the systemic inflammatory response in pneumococcal pneumonia. 61 54
19608588 2010
8
Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia. 54 61
19592208 2010
9
Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. 54 61
20236471 2010
10
CRP gene variation and risk of community-acquired pneumonia. 61 54
19947988 2010
11
Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. 54 61
19949732 2009
12
Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. 61 54
19548923 2009
13
Autoantibodies against bactericidal/permeability-increasing protein (BPI) in children with acute pneumonia. 61 54
19702878 2009
14
C-reactive protein to distinguish pneumonia from acute decompensated heart failure. 54 61
19703436 2009
15
Procalcitonin kinetics in Legionella pneumophila pneumonia. 61 54
19438643 2009
16
C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. 61 54
19729453 2009
17
Influence of age on symptoms and laboratory findings at presentation in patients with influenza-associated pneumonia. 61 54
19150140 2009
18
Old friends: pneumonia and interleukin-6. 61 54
19373054 2009
19
Role of IL-10 deficiency in pneumonia induced by Corynebacterium kutscheri in mice. 54 61
19421001 2009
20
C-reactive protein and community-acquired pneumonia in ambulatory care: systematic review of diagnostic accuracy studies. 54 61
19074757 2009
21
Mannose-binding lectin is present in the infected airway: a possible pulmonary defence mechanism. 61 54
18988662 2009
22
Suppression of pulmonary innate host defence in smokers. 54 61
18852155 2009
23
Mannose-binding lectin genotypes in susceptibility to community-acquired pneumonia. 54 61
18641104 2008
24
Children with absent surfactant protein D in bronchoalveolar lavage have more frequently pneumonia. 54 61
18266831 2008
25
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. 61 54
18508833 2008
26
Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury. 54 61
18403669 2008
27
Alveolar epithelial STAT3, IL-6 family cytokines, and host defense during Escherichia coli pneumonia. 54 61
18192501 2008
28
[Pneumocystis jiroveci pneumonia during infliximab therapy]. 54 61
18565304 2008
29
Resveratrol ameliorates Serratia marcescens-induced acute pneumonia in rats. 61 54
18174363 2008
30
C-reactive protein is an independent predictor of severity in community-acquired pneumonia. 54 61
18328306 2008
31
Assessment of B-type natriuretic peptide in patients with pneumonia. 61 54
17916178 2008
32
Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. 54 61
18252006 2008
33
[Detection of serum Th1 and Th2 cytokines and its significance in neonates with cytomegalovirus pneumonia]. 61 54
18322603 2007
34
Low mannose-binding lectin (MBL) levels in neonates with pneumonia and sepsis. 61 54
17711490 2007
35
Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. 61 54
17665457 2007
36
Infectious etiology modifies the treatment effect of zinc in severe pneumonia. 61 54
17684211 2007
37
Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. 61 54
17727747 2007
38
Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. 54 61
17334246 2007
39
Effects of specific neutrophil elastase inhibitor, sivelestat sodium hydrate, in murine model of severe pneumococcal pneumonia. 61 54
17454103 2007
40
Disease severity in patients with simultaneous influenza and bacterial pneumonia. 61 54
17603232 2007
41
Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. 54 61
17051484 2006
42
Modulation of the triggering receptor expressed on myeloid cells-1 pathway during pneumonia in rats. 54 61
16960786 2006
43
[Clinical features and outcome in 84 patients with influenza pneumonia]. 54 61
17087332 2006
44
Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion. 54 61
16891801 2006
45
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia. 54 61
16503423 2006
46
Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with pneumocystis pneumonia. 61 54
16709801 2006
47
Risk and prognostic factors of ventilator-associated pneumonia in trauma patients. 61 54
16484918 2006
48
[Diagnosis of nosocomial pneumonia: conventional and new indicators]. 61 54
17069202 2006
49
[Pseudomonas aeruginosa and Surfactant-associated Proteins A and D]. 54 61
16406431 2006
50
Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. 61 54
16956405 2006

Variations for Pneumonia

ClinVar genetic disease variations for Pneumonia:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FOXP3 NM_014009.3(FOXP3):c.1190G>A (p.Arg397Gln)SNV Pathogenic 379222 rs1057520529 X:49107901-49107901 X:49251440-49251440
2 TTR NM_000371.4(TTR):c.424G>A (p.Val142Ile)SNV Pathogenic/Likely pathogenic 13426 rs76992529 18:29178618-29178618 18:31598655-31598655
3 46;XX;t(2;3)(q34;p23)Translocation Likely pathogenic 267915

Expression for Pneumonia

Search GEO for disease gene expression data for Pneumonia.

Pathways for Pneumonia

Pathways related to Pneumonia according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TTR TNF TLR4 MUC5B MPO IL6
2
Show member pathways
13.9 TNF IL6 IL1B IL10 CXCL8 CXCL2
3
Show member pathways
13.76 TNF TLR4 IL6 IL1B IL10 CXCL8
4
Show member pathways
13.49 TNF TLR4 IL6 IL1B IL10 CXCL8
5
Show member pathways
13.45 TNF IL6 IL1B IL10 CXCL8 CXCL2
6
Show member pathways
13.39 TNF IL6 IL1B IL10 CXCL8 CXCL2
7
Show member pathways
13.15 TNF TLR4 SFTPD IL6 IL1B IL10
8
Show member pathways
13.04 TNF TLR4 IL6 IL1B CXCL8 CXCL2
9
Show member pathways
12.96 TNF IL6 IL1B IL10 FOXP3 CXCL8
10
Show member pathways
12.9 TNF TLR4 IL6 IL1B CXCL8 CCL2
11
Show member pathways
12.82 TNF TLR4 MUC5B IL6 IL1B CXCL8
12
Show member pathways
12.76 TNF TLR4 IL6 IL1B CD40LG
13
Show member pathways
12.71 TNF TLR4 IL6 IL1B IL10 CD40LG
14
Show member pathways
12.71